Drug details

Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)

type of HCV NS5A Inhibitors, HCV Polymerase Inhibitors, HCV Protease Inhibitors

Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir) is a fixed dose combination tablet that includes a hepatitis C virus NS5A inhibitor, a hepatitis C virus NS3/4A protease inhibitor, and a CYP3A inhibitor that inhibits CYP3A mediated metabolism of paritaprevir. Dasabuvir is a hepatitis C virus nonnucleoside NS5B palm polymerase inhibitor, which is supplied as separate tablets in the copackage. Taken with or without ribavirin, it is used for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.

The drug is often used to treat Cirrhosis , Hepatitis C .

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• upper stomach pain,
• loss of appetite,
• dark urine,
• yellowing of the skin or eyes (jaundice)
• confusion,
• clay-colored stool, and

The following drugs are related to Viekira Pak, either as a replacement or used together:

• Avonex (interferon beta-1a)
• Betaseron (interferon beta-1b)
• Victrelis (boceprevir capsules)
• Copegus (ribavirin)
• Zepatier (elbasvir and grazoprevir tablets)
• Neupogen (filgrastim injection)
• Releuko (filgrastim-ayow injection)
• Twinrix (hepatitis a inactivated & hepatitis b (recombinant) vaccine)
• Incivek (telaprevir film-coated tablets)
• Moderiba (ribavirin tablets)
• Ocaliva (obeticholic acid tablets)
• Olysio (simeprevir hard gelatin capsules)
• Peg-Intron (peginterferon alfa-2b)
• Pegasys (peginterferon alfa-2a)